Savara Inc (SVRA)

Etorro trading 970x250
Savara Inc (SVRA) Logo

About Savara Inc

Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas. Address: Building III, Austin, TX, United States, 78746

Savara Inc News and around…

Latest news about Savara Inc (SVRA) common stock and company :

Savara to Participate in Two Upcoming Investor Healthcare Conferences
15 Nov, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare conferences:

Savara Reports Third Quarter 2021 Financial Results and Provides Business Update
12 Nov, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter ending September 30, 2021 and provided a business update.

Savara to Present at the Jefferies London Healthcare Conference
10 Nov, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.

Savara to Present at the Inaugural Piper Sandler Lung Day
07 Oct, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a Fireside Chat at the Inaugural Piper Sandler Lung Day on Friday, October 15, 2021 at 10:30 am ET / 7:30 am PT.

3 Penny Stocks Insiders Are Buying
01 Oct, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Thursday 9/30 Insider Buying Report: SVRA, AXDX
30 Sep, 2021 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 Sep, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

Top Buys by Directors: Ramsay's $1.1M Bet on SVRA
31 Aug, 2021 FinancialContent

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Insider Buying: The Savara Inc. (NASDAQ:SVRA) Independent Director Just Bought 11% More Shares
22 Aug, 2021 Yahoo! Finance

Potential Savara Inc. ( NASDAQ:SVRA ) shareholders may wish to note that the Independent Director, David Ramsay...

5 Penny Stocks Insiders Are Buying
20 Aug, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
20 Aug, 2021 FinancialContent

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

12 Health Care Stocks Moving In Wednesday's After-Market Session
18 Aug, 2021 FinancialContent

Gainers Protagenic Therapeutics (NASDAQ:PTIX) stock increased by 32.79% to $2.47 during Wednesday's after-market session. Protagenic ...

Savara Reports Second Quarter 2021 Financial Results and Provides Business Update
12 Aug, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the second quarter ending June 30, 2021 and provided a business update.

Were Hedge Funds Right About Hycroft Mining Holding Corporation (HYMC)?
26 Jul, 2021 Yahoo! Finance

In this article we are going to use hedge fund sentiment as a tool and determine whether Hycroft Mining Holding Corporation (NASDAQ:HYMC) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League […]

First Week of SVRA September 17th Options Trading
16 Jul, 2021 FinancialContent

Investors in Savara Inc (SVRA) saw new options begin trading this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SVRA options chain for the new September 17th contracts and identified the following call contract of particular interest.

Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
01 Jul, 2021 Yahoo! Finance

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
30 Jun, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo. Molgramostim is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The trial is expected to be conducted at ~50 sites across the U.S., Canada, Japan, South Korea, and various countries in Europe and is anticipated to enroll ~160 patients with aPAP.

Implied Volatility Surging for Savara (SVRA) Stock Options
22 Jun, 2021 Yahoo! Finance

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Here is What Hedge Funds Think About Wrap Technologies, Inc. (WRAP)
18 Jun, 2021 Yahoo! Finance

In this article you are going to find out whether hedge funds think Wrap Technologies, Inc. (NASDAQ:WRAP) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Savara to Present at the Jefferies Virtual Healthcare Conference
26 May, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 AM ET / 7:00 AM PT.

Is Savara Inc. (NASDAQ:SVRA) Popular Amongst Institutions?
20 May, 2021 Yahoo! Finance

If you want to know who really controls Savara Inc. ( NASDAQ:SVRA ), then you'll have to look at the makeup of its...

Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
17 May, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT.

Savara Reports First Quarter 2021 Financial Results and Provides Business Update
13 May, 2021 FinancialContent

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the first quarter ending March 31, 2021 and provided a business update.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
05 May, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here at InvestorPlace, we're starting the day off like we always do with a look at the biggest pre-market stock movers for Wednesday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now

28 Stocks Moving in Wednesday's Pre-Market Session
05 May, 2021 FinancialContent

Gainers Athenex, Inc. (NASDAQ: ATNX) shares rose 46.6% to $5.44 in pre-market trading after the company announced it acquired Kuur ...

Wednesday 4/21 Insider Buying Report: RELL, SVRA
21 Apr, 2021 FinancialContent

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

Top Buys by Top Brass: CHIEF EXECUTIVE OFFICER Pauls's $149.8K Bet on SVRA
20 Apr, 2021 FinancialContent

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

First Week of June 18th Options Trading For Savara (SVRA)
19 Apr, 2021 FinancialContent

Investors in Savara Inc (SVRA) saw new options begin trading this week, for the June 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SVRA options chain for the new June 18th contracts and identified the following call contract of particular interest.

Penny Stocks To Buy According To Analysts With Price Targets Up to 341%
18 Apr, 2021 FinancialContent
7 Reddit Penny Stocks to Buy for a Biotech Boom
16 Apr, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm. The post 7 Reddit Penny Stocks to Buy for a Biotech Boom appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now

Savara Inc (SVRA) is a NASDAQ Common Stock listed in , ,

970x250